Literature DB >> 32253943

RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.

Nisha Jain1, Stefan Lethagen2,3.   

Abstract

Entities:  

Year:  2020        PMID： 32253943     DOI： 10.1080/03007995.2020.1744549

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN： 0300-7995            Impact factor:   2.580


× No keyword cloud information.
  1 in total

1.  Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.

Authors:  Robert Klamroth; Piotr Wojciechowski; Samuel Aballéa; Françoise Diamand; Zalmai Hakimi; Jameel Nazir; Lydia Abad-Franch; Stefan Lethagen; Elena Santagostino; Michael D Tarantino
Journal:  J Blood Med       Date:  2021-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.